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Objectives
Membrane bound receptor for advanced glycation end
products (RAGE) is over-expressed in response to
increasing concentrations of its ligand (eg S100A12) and
triggers an inflammatory immune response. Its trun-
cated form sRAGE acts as decoy receptor and competes
for ligands thus down-modulating inflammation.
Decreased sRAGE levels are associated with rheumatoid
arthritis, Sjogren syndrome and Kawasaki disease, how-
ever limited data is available in JIA thus we studied its
levels in JIA-ERA patients.
Methods
sRAGE levels were estimated in serum of patients with
ERA (n=101), SoJIA and polyJIA (n=10 each) and
healthy controls (n=45). Synovial fluid (SF) sRAGE was
measured in ERA, RA, ReA and OA patients (n=10).
S100A12 levels were also measured. 24 ERA patients
were followed up for 4 months. Disease activity was
assessed by swollen joint count (SJC), tender joint count
(TJC) and ESR.
Results
Serum sRAGE (pg/ml) level was significantly lower in
patients compared to healthy controls [515 (64-1887) vs
1542 (627-3159); p<0.0001]. In paired samples, SF had
lower levels compared to corresponding plasma level
[102 (51-799) vs 481 (134-1006); p<0.0001].
S100A12 (ng/ml) was higher in SF (1042; 573-1415)
than sera (638; 208-779). Serum sRAGE negatively cor-
related with S100A12 levels (r= -0.474; p<0.01.), ESR (r=
-0.306; p<0.01), SJC(r= -0.237; p<0.05) but not with TJC
(r= -0.134; p=ns). The levels of sRAGE remained stable
over time in patients with stable disease.
Conclusion
sRAGE levels are reduced in patients with ERA and
negatively correlate with disease activity and S100A12
levels. sRAGE may be a modulator of inflammation in
these patients.
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